Users Online: 497
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2018  |  Volume : 7  |  Issue : 2  |  Page : 91-95

Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer

1 Department of Medical Oncology, Patel Hospital, Jallandhar, Punjab, India
2 Department of Medical Oncology, Peerless Hospital, Kolkata, West Bengal, India
3 Department of Medical Oncology, SMH Curie Cancer Center, New Delhi, India
4 Department of Medical Oncology, Max Hospital, Noida, Uttar Pradesh, India
5 Department of Surgical Oncology, Indraprastha Apollo Hospital, New Delhi, India
6 Department of Medical Oncology, Dubai Health Authority, Dubai, UAE
7 Department of Medical Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka, India
8 Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
9 Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
10 Department of Medical Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India

Correspondence Address:
Dr. Vineet Talwar
Department of Medical Oncology, Rajiv Gandhi Cancer Institute, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sajc.sajc_109_18

Rights and Permissions

Bone-modifying therapy is a primary research interest in breast cancer. Several features contribute to the importance of the bone environment in the management of breast cancer. Firstly, bone metastases represent the most common site of breast cancer metastases and secondly, the emergence of cancer treatment-induced bone loss (CTIBL) among breast cancer survivors and patients is of increasing concern. In the adjuvant setting, bisphosphonates can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence. Expert oncologists discusses on the update on the approaches of Bone-modifying Agents and its treatment options. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded174    
    Comments [Add]    

Recommend this journal